Component
DL-propargylglycine, experimental CSE inhibitor
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
PAG coadministration lowered the SAC-associated CSE activity and eliminated the favorable infarct-size pattern; PAG alone also worsened injury.
Experimental context and source evidence
- acting_entity
- dl-propargylglycine
- availability_state
- machinery_impairment Imported condition classification; unverified.
- dose
- SAC 50 mg/kg/day; PAG 10 mg/kg/day
- duration
- Seven-day pretreatment; assessed 48 hours after infarction
- evidence_access
- Primary abstract
- experimental_comparison
- Saline, SAC, SAC plus PAG, and PAG-alone groups
- experimental_model
- Acute myocardial infarction; left ventricular and plasma measurements
- interpretation_status
- Source-derived research curation; not independent primary verification
- limitations
- Pharmacological interference, not a selective genetic proof; PAG-alone injury complicates attribution.
- nutrient_topic
- S-allylcysteine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · S-allyl-L-cysteine / SAC
- organism
- Rattus norvegicus
- plain_language
- Blocking the proposed pathway altered the outcome, with an important inhibitor control.
- primary_references
- [17766469] S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17766469/ · DOI 10.1152/ajpheart.00853.2007
- route
- Administration route not specified in accessed abstract
- tissue_or_cell_type
- Acute myocardial infarction; left ventricular and plasma measurements
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
S-allylcysteine: sulfur signaling, redox responses and cross-nutrient mechanisms (2026-09-20) · lines 257–264
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Acute myocardial infarction; left ventricular and plasma measurements · source_derived_draft · unverified_draft
## s-allylcysteine-pag-response Blocking the proposed pathway altered the outcome, with an important inhibitor control. PAG coadministration lowered the SAC-associated CSE activity and eliminated the favorable infarct-size pattern; PAG alone also worsened injury. Model: Acute myocardial infarction; left ventricular and plasma measurements Limitations: Pharmacological interference, not a selective genetic proof; PAG-alone injury complicates attribution. Evidence access: Primary abstract [17766469] S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17766469/ · DOI 10.1152/ajpheart.00853.2007 Structured context: {"organism": "Rattus norvegicus", "tissue_or_cell_type": "Acute myocardial infarction; left ventricular and plasma measurements", "dose": "SAC 50 mg/kg/day; PAG 10 mg/kg/day", "duration": "Seven-day pretreatment; assessed 48 hours after infarction", "route": "Administration route not specified in accessed abstract", "experimental_comparison": "Saline, SAC, SAC plus PAG, and PAG-alone groups", "acting_entity": "dl-propargylglycine", "interpretation_status": "Source-derived research curation; not independent primary verification"}
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.